Clinical Trials

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma


Study ID
Blue Bird CRB-402

NCT Number
NCT03274219 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0273

Principle Investigator
Dr. David Siegel

Phase
I

Sponsor
Bluebird Bio


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now